Home Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Free PDFs:
Hepatology 2014 (5th Edition, 612 pages)
Short Guide to Hepatitis C (2014 Edition, 206 pages)

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 69 articles:
HTML format
Text format



Single Articles


    July 2014
  1. GAMMONS MV, Lucas R, Dean R, Coupland SE, et al
    Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
    Br J Cancer. 2014 Jul 10. doi: 10.1038/bjc.2014.
    PubMed     Text format     Related articles    Abstract available


    June 2014
  2. CARLINO MS, Haydu LE, Kakavand H, Menzies AM, et al
    Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
    Br J Cancer. 2014 Jun 10. doi: 10.1038/bjc.2014.
    PubMed     Text format     Related articles    Abstract available


    April 2014
  3. AZIMI A, Pernemalm M, Frostvik Stolt M, Hansson J, et al
    Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.
    Br J Cancer. 2014 Apr 10. doi: 10.1038/bjc.2014.
    PubMed     Text format     Related articles    Abstract available


  4. JIANG G, Yang CS, Xu D, Sun C, et al
    Potent anti-tumour activity of a novel conditionally replicating adenovirus for melanoma via inhibition of migration and invasion.
    Br J Cancer. 2014 Apr 8. doi: 10.1038/bjc.2014.
    PubMed     Text format     Related articles    Abstract available


  5. WU S, Han J, Vleugels RA, Puett R, et al
    Cumulative ultraviolet radiation flux in adulthood and risk of incident skin cancers in women.
    Br J Cancer. 2014;110:1855-61.
    PubMed     Text format     Related articles    Abstract available


    March 2014
  6. CHIARION-SILENI V, Pigozzo J, Ascierto PA, Simeone E, et al
    Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.
    Br J Cancer. 2014 Mar 11. doi: 10.1038/bjc.2014.
    PubMed     Text format     Related articles    Abstract available


    February 2014
  7. SAND M, Georgas D, Hessam S, Bechara FG, et al
    Comment on 'Strong reduction of AGO2 expression in melanoma and cellular consequences'
    Br J Cancer. 2014 Feb 20. doi: 10.1038/bjc.2014.
    PubMed     Text format     Related articles   


  8. VOLLER D, Bosserhoff A
    Reply to comment on: strong reduction of AGO2 expression in melanoma and cellular consequences.
    Br J Cancer. 2014 Feb 20. doi: 10.1038/bjc.2014.
    PubMed     Text format     Related articles   


  9. POSCH C, Weihsengruber F, Bartsch K, Feichtenschlager V, et al
    Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients.
    Br J Cancer. 2014 Feb 11. doi: 10.1038/bjc.2014.
    PubMed     Text format     Related articles    Abstract available


  10. LI X, Wu XB, Chen Q
    Statin use is not associated with reduced risk of skin cancer: a meta-analysis.
    Br J Cancer. 2014;110:802-7.
    PubMed     Text format     Related articles    Abstract available


    January 2014
  11. DONO M, Angelini G, Cecconi M, Amaro A, et al
    Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma.
    Br J Cancer. 2014 Jan 14. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


    November 2013
  12. ADENIS A, Ray-Coquard I, Italiano A, Chauzit E, et al
    A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours.
    Br J Cancer. 2013;109:2574-8.
    PubMed     Text format     Related articles    Abstract available


  13. HEINZERLING L , Baiter M, Kuhnapfel S, Schuler G, et al
    Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations.
    Br J Cancer. 2013 Nov 5. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


    October 2013
  14. KHOSRAVI S , Wong RP, Ardekani GS, Zhang G, et al
    Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion.
    Br J Cancer. 2013 Oct 31. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


  15. VOLLER D , Reinders J, Meister G, Bosserhoff AK, et al
    Strong reduction of AGO2 expression in melanoma and cellular consequences.
    Br J Cancer. 2013 Oct 29. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


  16. LU J , Tang Y, Cheng Y, Zhang G, et al
    ING4 regulates JWA in angiogenesis and their prognostic value in melanoma patients.
    Br J Cancer. 2013 Oct 24. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


  17. BEDOGNETTI D , Spivey TL, Zhao Y, Uccellini L, et al
    CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.
    Br J Cancer. 2013 Oct 15. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


  18. OSAWA T, Ohga N, Akiyama K, Hida Y, et al
    Lysyl oxidase secreted by tumour endothelial cells promotes angiogenesis and metastasis.
    Br J Cancer. 2013;109:2237-47.
    PubMed     Text format     Related articles    Abstract available


    August 2013
  19. PLUMMER R , Lorigan P, Brown E, Zaucha R, et al
    Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma.
    Br J Cancer. 2013 Aug 29. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


    July 2013
  20. ZEBARY A , Jangard M, Omholt K, Ragnarsson-Olding B, et al
    KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.
    Br J Cancer. 2013 Jul 16. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


  21. MURTAS D , Maric D, De Giorgi V, Reinboth J, et al
    IRF-1 responsiveness to IFN-gamma predicts different cancer immune phenotypes.
    Br J Cancer. 2013;109:76-82.
    PubMed     Text format     Related articles    Abstract available


    June 2013
  22. GRIEWANK KG , Murali R, Schilling B, Scholz S, et al
    TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.
    Br J Cancer. 2013 Jun 25. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


  23. SHERRILL B , Wang J, Kotapati S, Chin K, et al
    Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma.
    Br J Cancer. 2013 Jun 20. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


  24. KOOPMANS AE , Vaarwater J, Paridaens D, Naus NC, et al
    Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11.
    Br J Cancer. 2013 Jun 18. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


  25. WHEELER BW , Kothencz G, Pollard AS
    Geography of non-melanoma skin cancer and ecological associations with environmental risk factors in England.
    Br J Cancer. 2013 Jun 11. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


    May 2013
  26. GRANN AF , Froslev T, Olesen AB, Schmidt H, et al
    The impact of comorbidity and stage on prognosis of Danish melanoma patients, 1987-2009: a registry-based cohort study.
    Br J Cancer. 2013 May 16. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


  27. BOECKE A , Carstens AC, Neacsu CD, Baschuk N, et al
    TNF-receptor-1 adaptor protein FAN mediates TNF-induced B16 melanoma motility and invasion.
    Br J Cancer. 2013 May 14. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


  28. MILLWARD M , Underhill C, Lobb S, McBurnie J, et al
    Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.
    Br J Cancer. 2013 May 7. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


    April 2013
  29. HEINZERLING L , Kuhnapfel S, Meckbach D, Baiter M, et al
    Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice.
    Br J Cancer. 2013 Apr 11. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


    March 2013
  30. O'BOYLE G , Swidenbank I, Marshall H, Barker CE, et al
    Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.
    Br J Cancer. 2013 Mar 28. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


  31. EL HAJJ P , Journe F, Wiedig M, Laios I, et al
    Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients.
    Br J Cancer. 2013 Mar 21. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


  32. KURIHARA M , Kirita T, Sasahira T, Ohmori H, et al
    Protumoral roles of melanoma inhibitory activity 2 in oral squamous cell carcinoma.
    Br J Cancer. 2013 Mar 19. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


    February 2013
  33. WILMOTT JS , Menzies AM, Haydu LE, Capper D, et al
    BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.
    Br J Cancer. 2013 Feb 12. doi: 10.1038/bjc.2013.
    PubMed     Text format     Related articles    Abstract available


    October 2012
  34. ALI Z , Fisher R, Larkin J
    Targeted therapeutics in melanoma.
    Br J Cancer. 2012;107:1663.
    PubMed     Text format     Related articles   


    September 2012
  35. GIRARD E , Strathdee C, Trueblood E, Queva C, et al
    Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model.
    Br J Cancer. 2012 Sep 6. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available


    August 2012
  36. SEGUIN F , Carvalho MA, Bastos DC, Agostini M, et al
    The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas.
    Br J Cancer. 2012 Aug 14. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available


    July 2012
  37. KRUIJFF S , Bastiaannet E, Francken AB, Schaapveld M, et al
    Breslow thickness in the Netherlands: a population-based study of 40 880 patients comparing young and elderly patients.
    Br J Cancer. 2012;107:570-4.
    PubMed     Text format     Related articles    Abstract available


  38. WEIDE B , Elsasser M, Buttner P, Pflugfelder A, et al
    Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis.
    Br J Cancer. 2012 Jul 10. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available


  39. PECUCHET N , Lebbe C, Mir O, Billemont B, et al
    Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
    Br J Cancer. 2012 Jul 5. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available


    April 2012
  40. FEUN LG , Marini A, Walker G, Elgart G, et al
    Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
    Br J Cancer. 2012 Apr 3. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available


    March 2012
  41. WANG H , Lee S, Nigro CL, Lattanzio L, et al
    NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity.
    Br J Cancer. 2012 Mar 27. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available


  42. HENARE K , Wang L, Wang LC, Thomsen L, et al
    Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.
    Br J Cancer. 2012;106:1134-47.
    PubMed     Text format     Related articles    Abstract available


  43. YAMAMOTO K , Ohga N, Hida Y, Maishi N, et al
    Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells.
    Br J Cancer. 2012;106:1214-23.
    PubMed     Text format     Related articles    Abstract available


    February 2012
  44. THOMAS S , Putter C, Weber S, Bornfeld N, et al
    Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study.
    Br J Cancer. 2012 Feb 21. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available


    January 2012
  45. WALDMANN A , Nolte S, Weinstock MA, Breitbart EW, et al
    Skin cancer screening participation and impact on melanoma incidence in Germany - an observational study on incidence trends in regions with and without population-based screening.
    Br J Cancer. 2012 Jan 31. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available


  46. SAKAIZAWA K , Goto Y, Kiniwa Y, Uchiyama A, et al
    Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level.
    Br J Cancer. 2012 Jan 26. doi: 10.1038/bjc.2012.
    PubMed     Text format     Related articles    Abstract available


  47. XU Y , Brenn T, Brown ER, Doherty V, et al
    Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors.
    Br J Cancer. 2012 Jan 5. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available


    December 2011
  48. PARKIN DM , Mesher D, Sasieni P
    13. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010.
    Br J Cancer. 2011;105 Suppl 2:S66-9.
    PubMed     Text format     Related articles   


    November 2011
  49. ALGAZI AP , Weber JS, Andrews SC, Urbas P, et al
    Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
    Br J Cancer. 2011 Nov 29. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available


  50. JANJETOVIC Z , Brozyna AA, Tuckey RC, Kim TK, et al
    High basal NF-kappaB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives.
    Br J Cancer. 2011 Nov 17. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available


  51. JOURNE F , Boufker HI, Van Kempen L, Galibert MD, et al
    TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome.
    Br J Cancer. 2011 Nov 1. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available


    October 2011
  52. KEIDAR M , Walk R, Shashurin A, Srinivasan P, et al
    Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy.
    Br J Cancer. 2011;105:1295-301.
    PubMed     Text format     Related articles    Abstract available


  53. JOHNSON KJ , Carozza SE, Chow EJ, Fox EE, et al
    Birth characteristics and childhood carcinomas.
    Br J Cancer. 2011;105:1396-401.
    PubMed     Text format     Related articles    Abstract available


  54. FUKUDA H , Mochizuki S, Abe H, Okano HJ, et al
    Host-derived MMP-13 exhibits a protective role in lung metastasis of melanoma cells by local endostatin production.
    Br J Cancer. 2011 Oct 20. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available


    September 2011
  55. GRIGNOL V , Fairchild ET, Zimmerer JM, Lesinski GB, et al
    miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions.
    Br J Cancer. 2011;105:1023-9.
    PubMed     Text format     Related articles    Abstract available


  56. WEST EJ , Scott KJ, Jennings VA, Melcher AA, et al
    Immune activation by combination human lymphokine-activated killer and dendritic cell therapy.
    Br J Cancer. 2011;105:787-95.
    PubMed     Text format     Related articles    Abstract available


    August 2011
  57. DE LUCA A , Lamura L, Strizzi L, Roma C, et al
    Expression and functional role of CRIPTO-1 in cutaneous melanoma.
    Br J Cancer. 2011 Aug 23. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available


  58. TAWBI HA , Villaruz L, Tarhini A, Moschos S, et al
    Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours.
    Br J Cancer. 2011 Aug 2. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available


    July 2011
  59. O'DAY S , Pavlick A, Loquai C, Lawson D, et al
    A randomised, phase II study of intetumumab, an anti-alpha(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma.
    Br J Cancer. 2011 Jul 12. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available


  60. EISEN T , Marais R, Affolter A, Lorigan P, et al
    Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
    Br J Cancer. 2011 Jul 12. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available


  61. GREMEL G , Ryan D, Rafferty M, Lanigan F, et al
    Functional and prognostic relevance of the homeobox protein MSX2 in malignant melanoma.
    Br J Cancer. 2011 Jul 5. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available


    June 2011
  62. SIGALOTTI L , Fratta E, Parisi G, Coral S, et al
    Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
    Br J Cancer. 2011 Jun 21. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles   


  63. BRAIG S , Wallner S, Junglas B, Fuchshofer R, et al
    CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration.
    Br J Cancer. 2011 Jun 14. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available


  64. DEBLACAM C , Byrne C, Hughes E, McIlroy M, et al
    HOXC11-SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib.
    Br J Cancer. 2011 Jun 7. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available


    May 2011
  65. CHIARION-SILENI V , Guida M, Ridolfi L, Romanini A, et al
    Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available


    March 2011
  66. REUSCHENBACH M , Tran T, Faulstich F, Hartschuh W, et al
    High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available


  67. KHAN OA , Gore M, Lorigan P, Stone J, et al
    A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.
    Br J Cancer. 2011;104:750-5.
    PubMed     Text format     Related articles    Abstract available


  68. KUROSU T , Ohga N, Hida Y, Maishi N, et al
    HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium.
    Br J Cancer. 2011;104:819-29.
    PubMed     Text format     Related articles    Abstract available


    February 2011
  69. WANG Y , Wang XY, Subjeck JR, Shrikant PA, et al
    Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines.
    Br J Cancer. 2011;104:643-52.
    PubMed     Text format     Related articles   


Thank you for your interest in scientific medicine.


All AMEDEO services are free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Amedeo is a Flying Publisher website.

   Design: